Corrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": [ESMO Open 3 (2018) e000375]
ESMO Open. 2023 Apr;8(2):101185.
doi: 10.1016/j.esmoop.2023.101185.
Epub 2023 Mar 1.
1 Department of Medical, Oncology, Center Georges Francois Leclerc, Dijon, France; Research Platform in Biological Oncology, Georges Francois Leclerc Center, Dijon, France; University of Burgundy-Franche Comté, Dijon, France. Electronic address: jd.fumet@gmail.com.
2 Department of Medical, Oncology, Center Georges Francois Leclerc, Dijon, France.
3 Department of Epidemiology and Biostatistics, Georges, François Leclerc Center, Dijon, France.
4 Department of Medical, Oncology, Center Georges Francois Leclerc, Dijon, France; Research Platform in Biological Oncology, Georges Francois Leclerc Center, Dijon, France; University of Burgundy-Franche Comté, Dijon, France; INSERM UMR1231, Dijon, France; GIMI Genetic and Immunology, Medical Institute, Dijon, France.